Trials / Terminated
TerminatedNCT04162301
A Study of CS3002 in Subjects With Advanced Solid Tumors
A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activities of CS3002, a CDK4/6 Inhibitor, in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS3002 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS3002 | CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration. |
Timeline
- Start date
- 2019-12-30
- Primary completion
- 2021-02-19
- Completion
- 2021-02-19
- First posted
- 2019-11-14
- Last updated
- 2021-04-15
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04162301. Inclusion in this directory is not an endorsement.